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Abstract We studied the A55T, E164K, I225T,
K153R and P198A variants in the myostatin (GDF8)
gene, muscle strength and mass, and physical function
during daily living in 41 nonagenarians [33 women,
age range, 90, 97]. No participant carried a mutant
allele of the aforementioned variants, except three
participants (all women), who carried the R allele of
the K153R polymorphism, with one of them (woman
aged 96 years) being homozygous. Overall, in KR
women muscle phenotype values (1RM leg press and
estimated muscle mass) were low-to-normal com-
pared to the whole group (∼25th–50th percentile), and
their functional capacity (Barthel and Tinetti tests)
was normal. In the woman bearing the RR genotype,
values of muscle mass and functional capacity were
below the 25th percentile. She is the first RR
Caucasian whose phenotype has been characterised
specifically. In summary, heterozygosity for the
GDF8 K153R polymorphism does not seem to exert
a negative influence on the muscle phenotypes of
women who are at the end of the human lifespan, yet
homozygosity might do so. More research on larger
cohorts of nonagenarians is needed to corroborate the
present findings.
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Introduction
The number of people approaching the theoretical
endpoint of the human lifespan is increasing. In
elderly people, functional capacity is directly depen-
dent on muscular fitness as these persons typically
experience age-associated declines in skeletal muscle
mass and strength, i.e., sarcopenia (Brooks and
Faulkner 1994; van Dijk et al. 2005). Sarcopenia
contributes to the decreased capacity for independent
living and reduced ability to cope with activities of
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daily life (ADLs), increasing the burden for the
caregiver and community (Serra Rexach et al. 2009).
To identify the factors that influence muscle fitness at
the end of the human lifespan is of clinical and public
health interest. Genetics is one of these factors. There
are candidate genes that may explain individual
variations in muscle fitness, such as unfavourable
genotypes potentially associated with accelerated
sarcopenia.
The myostatin (MSTN or growth differentiation
factor 8, GDF8 [MIM601788]) gene is receiving
growing attention (Huygens et al. 2004). It encodes
myostatin, a skeletal muscle-specific secreted
peptide that functions to limit muscle growth
(McPherron et al. 1997). In transgenic animal
models, prolonged absence of myostatin reduces
sarcopenia (Siriett et al. 2006). Systemic treatment
with myostatin inhibitors provides an adequate
safety margin for clinical studies (Wagner et al.
2008). Whereas Wagner et al. (2008) did not show
improvements in muscle strength or function, they
observed that a few individuals had an increased
muscle size (as measured with dual-energy radio-
graphic absorptiometry and muscle histology), sup-
porting the bioactivity of myostatin inhibitors.
Several polymorphisms and mutations have been
identified in the GDF8 gene with diverse functional
consequences. Of the identified polymorphisms, the
Lys(K)153Arg(R) variation located in exon 2
(rs1805086, 2379 A>G replacement) is a candidate
to influence skeletal muscle phenotypes. The frequen-
cy of the mutant R allele is of about 3–4% among
Caucasians, with a frequency of mutant homozygotes
(RR) below 1% (Corsi et al. 2002; Ferrell et al. 1999;
Kostek et al. 2009). Such low allelic frequency
certainly limits the possibility of studying large
groups of people carrying the R variant. Though
controversy exists with regards to adults (Kostek et al.
2009), the K153R polymorphism is associated with
muscle strength, with the infrequent mutant R allele
possibly exerting a negative influence in old (yet
<80 years) Caucasian people (Ferrell et al. 1999;
Huygens et al. 2004; Seibert et al. 2001).
It was the purpose of this study to assess the
association of the GDF8 K153R polymorphism
with muscle phenotypes and functional capacity
during ADLs in Spanish (Caucasian) nonagenarians.
We also genotyped the GDF8 variants A55T
(rs1805065, located in exon 1), and E164K
(rs35781413), I225T and P198A (all located in
exon 2).
Materials and methods
A total of 41 (n=33 women) nonagenarians (age range,
90–97 years) were recruited from a geriatric nursing
home (Los Nogales-Pacífico, Madrid, Spain) and
received a comprehensive medical examination. Inclu-
sion criteria were: age ≥90 years, able to ambulate with
or without assistance, able to communicate and being
capable and willing to provide consent. Exclusion
criteria were acute or terminal illness, myocardial
infarction in the past 3 months, unstable cardiovascular
disease, upper or lower extremity fracture in the past
3 months, severe dementia and presence of neuromus-
cular disease or drugs affecting neuromuscular func-
tion. The Medical Ethics Committee of Hospital
General Universitario Gregorio Marañón (Madrid,
Spain) approved the study and all participants provided
written informed consent.
We assessed dynamic muscular strength of the
lower body by estimating one repetition maximum
(1RM) seated leg press (Technogym, Barcelona,
Spain) (Brzycki 1993; Serra Rexach et al. 2009).
Initial loads were 70–100% of body weight. Follow-
ing a brief rest period, increments of 2–4 kg were
added until maximal effort was achieved for each lift,
usually after 5 trials or less. All participants were able
to lift the initial load at least one time. Participants
were instructed on proper breathing and lifting form
for each movement (Serra Rexach et al. 2009). We
estimated whole-body muscle mass as detailed else-
where (Lee et al. 2000).
We assessed participants' gait and balance abilities
using the Tinetti scale (Tinetti 1986). For gait
evaluation, the subject stands with the examiner,
walks across the room, first at “usual” pace, then
back at “rapid, but safe” pace (utilising usual walking
aids) and the following tasks are scored (0 to 2,
indicating highest to lowest level of impairment
respectively): initiation of gait, step length and height,
step symmetry, step continuity, path, trunk sway and
walking stance. For balance evaluation, the subject is
seated in a hard, armless chair and the following
manoeuvres are tested (score, 0, 1 or 2): sitting
balance, arises, attempts to arise, immediate standing
balance (first 5 s), standing balance, ‘nudged’, eyes
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closed, turning 360° and sitting down. The maximum
sum-score of both gait and balance components is 28
points. Patients who score below 24 are at risk for
falls, and the risk of falling is high with a score below
19. The validity of this test for screening old adults at
risk for falling is well established (Raiche et al. 2000).
We also determined the participant's ability to
perform ADLs independently with the Barthel score
(Mahoney and Barthel 1965). The Barthel index is a
valid instrument that is widely used to measure the
capacity of a person for the execution of ten basic
activities in daily life, obtaining a quantitative
estimation of the individual's level of independency
(Collin et al. 1988; Mahoney and Barthel 1965). The
ten items include eating, transferring from bed to
chair, using the toilet, bathing/showering, personal
hygiene (tooth brushing, shaving) dressing, walking,
stair climbing and bowel and bladder control. Each
individual item is scored with 0 (unable to perform
without complete help), 5 (able to perform the activity
with little help) or 10 (able to perform without any
help). The sum-score ranges from 0 (totally depen-
dent) to 100 (totally independent).
Sequences corresponding to the A55T, E164K,
I225T, K153R and P198A variants were amplified by
the polymerase chain reaction (PCR) during early fall
2009 (for E164K, I225T, K153R and P198A) and late
January 2010 (for A55T) in the Genetics Laboratory of
the Universidad Europea de Madrid. The primers used
for the A55T variant were: 5′-CAAGTTGTCTCTCA-
GACTG-3′ and 5′-CAACAGTCAGCAGAACTGT-3′.
The primers used for the other variants were 5′-
GAAAACCCAAATGTTGCTTC-3′ and 5′-TGTCT
AGCTTATGAGCTTAGGG-3′. The PCR conditions
were as follows: initial denaturing at 95°C for 10 min;
35 cycles at 95°C for 1 min, 52°C for 45 s, 72°C for
1 min and a final extension at 72°C for 5 min.
The resulting PCR products were genotyped by
single base extension (SBE) (Juffer et al. 2009). The
primers used for A55T, E164K, I225T K153R and
P198A were 5′CTAAATCTTCAAGAATAGAA-3′,
5′-CAAACACTGTTGTAGGAGTCT-3′, 5′-CTG
AATCCAACTTAGGCA-3′, 5′-TTTAATACAATA
CAATAAAGTAGTAA-3 ′, and 5 ′-TTTTTTTT
ATCTCTGAAACTTGACATGAAC-3′, respectively.
The PCR SBE conditions were 96°C for 10 s; 25
cycles at 50°C for 5 s and 60°C for 30 s. The resulting
PCR products were detected in an ABI PRISM
(Applied Biosystems, Foster City, CA).
Results and discussion
Genotype success was 100%. No participant carried
the mutant allele of any of the A55T, E164K, I225T
and P198A variants, whereas three participants (all
women) carried the R allele of the K153R polymor-
phism (total allelic frequency=4.9%), with one of
them (woman aged 96 years) being homozygous. This
is the first RR genotype that we have found for the
GDF8 K153R polymorphism in our entire DNA-base
of Spanish population (∼500 samples). To our
knowledge, there is no available information regard-
ing the muscle strength phenotypes of the few RR
Caucasians that have been reported to exist. Corsi et
al. (2002) found an old Italian person (assumed age
<80 years) with the RR genotype, yet with no
specification on individual phenotype data.
Figures 1 and 2 show the individual values of
muscle strength and functional capacity phenotypes
respectively. Overall, in the two KR women (labelled
as # 1 and # 2 in Figs. 1 and 2) muscle phenotype
values were low-to-normal compared to the whole
group (∼25th–50th sex-specific percentile) and their
functional capacity during daily living was normal. In
the woman with the RR genotype, values of muscle
mass and functional capacity were below the 25th
sex-specific percentile. To note was her almost null
gait and balance ability (Tinetti scale) and her low
capacity for performing ADLs independently (Barthel
score) (Fig. 2).
The results should be taken as preliminary due to
the small sample size of our cohort, yet we believe
this is justifiable owing to the uniqueness of the
studied population group and the low frequency of the
R allele among Caucasians. Overall, our data suggest
that, except in the few rare cases of homozygosity, the
R allele of the GDF8 K153R polymorphism is not
associated with accelerated sarcopenia in humans who
are near the end of the lifespan. Recent research from
our laboratory showed that heterozygosity for this
variation can alter the functional capacity of adult
women, yet their muscle function was already altered
by an inherited myopathy (Gonzalez-Freire et al.
2009). Although more research is needed, the GDF8
K153R polymorphism has the potential to alter the
function of the GDF8 gene (Ferrell et al. 1999;
Saunders et al. 2006), as briefly explained below.
Myostatin enters the bloodstream as a latent precursor
protein and then undergoes a proteolytic process to
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become a mature peptide (free from the propeptide)
that binds to extracellular activin type II receptor
(ActRIIB) (Kostek et al. 2009). Binding of myostatin
to ActRIIB induces intracellular activation of Smad
proteins; through this pathway, myostatin modulates
myoblast proliferation (Thomas et al. 2000) and
differentiation (Ríos et al. 2002), and thus ultimately
muscle mass. The Lys(K)153Arg(R) amino acid
replacement is found within the active mature peptide
of the myostatin protein and could theoretically
influence (1) proteolytic processing with its propep-
tide or (2) affinity to bind with ActRIIB (Lee and
McPherron 2001; Jiang et al. 2004). This in turn
would result in inability of myostatin to modulate
muscle mass and strength (Kostek et al. 2009).
In summary, and while keeping in mind that more
research with larger population samples is necessary,
heterozygosity for the GDF-8 K153R polymorphism
does not seem to exert a negative influence on the
muscle strength and functional capacity of women
who are at the end of the human lifespan, whereas
homozygosity seems to impair these phenotypes. The
RR genotype might explain some ‘extreme’ sarcope-
nia phenotypes among old humans. It must be
however emphasised that phenotype traits indicative
of muscle function in the elderly are probably
complex and thus not likely to be reducible to the
influence of a few single polymorphisms.
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Fig. 2 Individual data of functional capacity tests. Abbreviations: perc. (sex-specific percentile)
Fig. 1 Individual data of muscle phenotypes in all women. Abbreviations: perc. (sex-specific percentile)
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